# Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

> **NCT00262886** · PHASE2 · COMPLETED · sponsor: **University of Rochester** · enrollment: 35 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **BIOLOGICAL:** graft-versus-tumor induction therapy
- **BIOLOGICAL:** therapeutic allogeneic lymphocytes
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **DRUG:** mycophenolate mofetil
- **DRUG:** tacrolimus
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00262886
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2013-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00262886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00262886, "Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00262886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*